CLAIMS

1. A compound of Formula (I):



(I);

or a hydrate, solvate, or pharmaceutically acceptable salt thereof, wherein:

**$R_1$** is (a) $C_8$-$C_{16}$ polycyclic cycloalkyl optionally substituted by one or more **$R_6$**,

(b) benzofuranyl or dihydrobenzofuranyl, wherein the benzofuranyl or dihydrobenzofuranyl is optionally substituted by one or more **$R_6$**;

(c) , , or ;

(d) ; or

(e) , , , , , , , , , , , , , , .



**$R_3$** is H, methyl, or ethyl, wherein the methyl or ethyl is optionally substituted with one or more **$R_7$**;

**$R_4$** is H, $C_1$-$C_6$ alkyl, -$(CH_2)_{0-3}$-($C_3$-$C_6$ cycloalkyl), or -$(CH_2)_{0-3}$-$C_5$-$C_6$ aryl;

**$R_6$** is $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_1$-$C_6$ alkoxy, $C_3$-$C_8$ cycloalkyl, halo, oxo, -OH, -CN, -$NH_2$, -NH($C_1$-$C_6$ alkyl), -N($C_1$-$C_6$ alkyl)$_2$, -$CH_2F$, -$CHF_2$, or -$CF_3$;

**$R_7$** is –$OR_8$, $C_5$-$C_{10}$ aryl, or 5- to 10- membered heteroaryl, wherein the $C_5$-$C_{10}$ aryl or 5- to 10-membered heteroaryl is optionally substituted by one or more **$R_{7S}$**, wherein each **$R_{7S}$** is independently $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, 5- to 10-membered heteroaryl, halo, -OH, -CN, -

$(CH_2)_{0-3}$-$NH_2$, -$(CH_2)_{0-3}$-NH($C_1$-$C_6$ alkyl), -$(CH_2)_{0-3}$-N($C_1$-$C_6$ alkyl)$_2$, -$CH_2F$, -$CHF_2$, or -$CF_3$; and

**$R_8$** is $C_1$-$C_6$ alkyl or 5- to 7-membered heterocycloalkyl, wherein the $C_1$-$C_6$ alkyl or 5- to 7-membered heterocycloalkyl is optionally substituted by one or more **$R_{7S}$**.

2. The compound of claim 1, wherein **$R_1$** is $C_8$-$C_{16}$ polycyclic cycloalkyl substituted by one or more $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_1$-$C_6$ alkoxy, $C_3$-$C_8$ cycloalkyl, halo, oxo, -OH, -CN, -$NH_2$, -NH($C_1$-$C_6$ alkyl), -N($C_1$-$C_6$ alkyl)$_2$, -$CH_2F$, -$CHF_2$, or -$CF_3$.

3. The compound of claim 1, wherein **$R_1$** is



.

4. The compound of claim 1, wherein **$R_3$** is methyl or ethyl, wherein the methyl or ethyl is optionally substituted with one or more –$OR_8$, $C_5$-$C_{10}$ aryl, or 5- to 10- membered heteroaryl.

5. The compound of claim 1, wherein **$R_3$** is methyl substituted with one or more 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is optionally substituted with one or more $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkoxy, halo, -CN, -$(CH_2)_{0-3}$-N($C_1$-$C_6$ alkyl)$_2$, or -$CF_3$.

6. The compound of claim 1, wherein **$R_3$** is , , , , , , , , .





7. The compound of claim 1, wherein **$R_4$** is H.

8. The compound of claim 1, wherein **$R_4$** is $C_1$-$C_6$ alkyl, -$(CH_2)_{0-3}$-($C_3$-$C_6$ cycloalkyl), or -$(CH_2)_{0-3}$-$C_5$-$C_6$ aryl.

9. The compound of claim 1, wherein **$R_4$** is methyl, ethyl, propyl, or butyl, 





10. The compound of claim 1, wherein at least one $\mathbf{R_7}$ is 5- to 10-membered heteroaryl optionally substituted by one or more halo, -OH, -CN, -$(CH_2)_{0-3}$-$NH_2$, -$(CH_2)_{0-3}$-$NH(C_1$-$C_6$ alkyl), -$(CH_2)_{0-3}$-$N(C_1$-$C_6$ alkyl$)_2$, -$CH_2F$, -$CHF_2$, or -$CF_3$.

11. The compound of claim 1, being of Formula (Ia), (Ib), (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (IVa), (IVb), (V), (Va), (Vb), (VI), (VIa), (VIb), VII), (VIIa), (VIIb), (VIII), (VIIIa), (VIIIb), (IX), (IXa), (IXb), (X), (Xa), or (Xb):


(Ia);


(Ib);


(II);


(IIa);


(IIb);


(III);



(IIIa);



(IIIb);



(IV);



(IVa);



(IVb);



(V);



(Va);



(Vb);



(VI);



(VIa);



(VIb);



(VII);



(VIIa);



(VIIb);



(VIII);



(VIIIa);



(VIIIb);



(IX);



(IXa);



(IXb);



(X);



(Xa);



(Xb);

or a hydrate, solvate, or pharmaceutically acceptable salt thereof.

12. The compound of any one of claims 1-11, being selected from Compound Nos. 1-8, 10-52, 55, 57-86, 88-117, 119-121, 123-128 and 130 and pharmaceutically acceptable salts thereof:

| Compound No. | Structure | Name |
|---|---|---|
| 1 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate |
| 2 |  | Ethyl 2-{[(2,6-difluorophenyl)carbamoyl]oxy}acetate |
| 3 |  | Ethyl 2-{[(2,6-dichlorophenyl)carbamoyl]oxy}acetate |
| 4 |  | Ethyl 2-{[(naphthalen-1-yl)carbamoyl]oxy}acetate |
| 5 |  | Ethyl 2-{[(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)carbamoyl]oxy}acetate |
| 6 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-methoxypropanoate |
| 7 |  | Ethyl 2-({[2-fluoro-5-(trifluoromethyl)phenyl]carbamoyl}oxy)acetate |

| Compound No. | Structure | Name |
|---|---|---|
| 8 |  | Ethyl 2-{[(2,6-dimethylphenyl)carbamoyl]oxy}acetate |
| 10 |  | Ethyl 2-({[2-(chloro-6-methylphenyl)carbamoyl]oxy}acetate |
| 11 |  | Ethyl 2-{[(2-cyanophenyl)carbamoyl]oxy}acetate |
| 12 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyridin-3-yl)propanoate |
| 13 |  | Ethyl 2-{[(2-tert-butylphenyl)carbamoyl]oxy}acetate |
| 14 |  | Ethyl 2-((mesitylcarbamoyl)oxy)acetate |
| 15 |  | Ethyl 2-(((2-isopropylphenyl)carbamoyl)oxy)acetate |
| 16 |  | Ethyl 2-(((2-ethyl-6-methylphenyl)carbamoyl)oxy)acetate |

| Compound No. | Structure | Name |
|---|---|---|
| 17 |  | Ethyl 2-(((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)oxy)-3-phenylpropanoate |
| 18 |  | Ethyl 2-(((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)oxy)-3-(pyridin-2-yl)propanoate |
| 19 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 20 |  | Propan-2-yl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate |
| 21 |  | 2-{[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate |
| 22 |  | Cyclopropylmethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate |
| 23 |  | Cyclobutyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate |

| Compound No. | Structure | Name |
|---|---|---|
| 24 |  | 2-methylpropyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate |
| 25 |  | Ethyl 3-(4-cyanophenyl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 26 |  | Ethyl 2-({[2-methyl-6-(propan-2-yl)phenyl]carbamoyl}oxy)acetate |
| 27 |  | 2-{[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetic acid |
| 28 |  | Ethyl 2-{[(2,6-diethyl-4-methylphenyl)carbamoyl]oxy}acetate |
| 29 |  | Methyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate |
| 30 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-4-phenylbutanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 31 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 32 |  | Cyclopentyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate |
| 33 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-imidazol-1-yl)propanoate |
| 34 |  | Ethyl 2-({[2,6-bis(propan-2-yl)phenyl]carbamoyl}oxy)acetate |
| 35 |  | Ethyl 2-({[2-chloro-5-(trifluoromethyl)phenyl]carbamoyl}oxy)acetate |
| 36 |  | Ethyl 2-{[(2-tert-butyl-6-methylphenyl)carbamoyl]oxy}acetate |
| 37 |  | Ethyl 2-{[(2,5-dimethylphenyl)carbamoyl]oxy}acetate |

| Compound No. | Structure | Name |
|---|---|---|
| 38 |  | 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-methoxypropanoic acid |
| 39 |  | cyclopropyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}acetate |
| 40 |  | 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoic acid |
| 41 |  | Ethyl (2R)-3-(3-cyanophenyl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 42 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-[3-(1H-pyrazol-1-yl)phenyl]propanoate |
| 43 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-[3-(1H-pyrazol-1-yl)phenyl]propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 44 |  | Ethyl 2-{[(2,6-difluorophenyl)carbamoyl]oxy}-3-1H-pyrazol-1-yl)propanoate |
| 45 |  | Ethyl 2-[(phenylcarbamoyl)oxy]-3-(1H-pyrazol-1-yl)propanoate |
| 46 |  | Ethyl 2-{[(2-ethyl-6-methylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 47 |  | Ethyl 2-{[(2,6-dimethylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 48 |  | Ethyl 2-{[(2,6-diethylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 49 |  | Ethyl 2-{[(2-fluoro-6-methylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 50 |  | Ethyl 2-{[(2-chloro-6-fluorophenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 51 |  | Ethyl 2-{[(2-chloro-6-methylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 52 |  | Ethyl 2-{[(2,6-dichlorophenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 55 |  | Ethyl 3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 57 |  | Ethyl 2-{[(2-cyano-6-methylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 58 |  | Ethyl 2-{[(2-cyano-6-ethylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 59 |  | Ethyl 2-{[(2-chloro-6-cyanophenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 60 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrazin-2-yl)propanoate |
| 61 |  | (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoic acid |
| 62 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyridazin-3-yl)propanoate |
| 63 |  | Ethyl 3-(1H-pyrazol-1-yl)-2-{[(2,3,6-trifluorophenyl)carbamoyl]oxy}propanoate |
| 64 |  | Benzyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 65 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 66 |  | Ethyl 2-{[(2-ethyl-6-fluorophenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 67 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-imidazol-1-yl)propanoate |
| 68 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-methoxypropanoate |
| 69 |  | (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-methoxypropanoic acid |
| 70 |  | Ethyl 2-({[2-chloro-3-(trifluoromethyl)phenyl]carbamoyl}oxy)-3-(1H-pyrazol-1-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 71 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-1,2,4-triazol-1-yl)propanoate |
| 72 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(3-methyl-1H-pyrazol-1-yl)propanoate |
| 73 |  | Ethyl 3-(1H-pyrazol-1-yl)-2-{[(2,4,6-trifluorophenyl)carbamoyl]oxy}propanoate |
| 74 |  | Ethyl 2-({[2-methyl-6-(propan-2-yl)phenyl]carbamoyl}oxy)-3-(1H-pyrazol-1-yl)propanoate |
| 75 |  | Ethyl 2-{[(3-chloro-2,6-difluorophenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 76 |  | Ethyl (2R)-3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 77 |  | Benzyl (2R)-3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 78 |  | Ethyl 2-{[(2,6-dimethylphenyl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate |
| 79 |  | (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-imidazol-1-yl)propanoic acid |
| 80 |  | Ethyl 3-(4-fluoro-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 81 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(5-methyl-1H-imidazol-1-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 82 |  | (2R)-3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoic acid |
| 83 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-1,2,4-triazol-1-yl)propanoate |
| 84 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(2-methyl-1H-imidazol-1-yl)propanoate |
| 85 |  | Ethyl 2-{[(2-chloro-6-ethylphenyl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 86 |  | Ethyl 2-{[(2-methylnaphthalen-1-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |
| 88 |  | Ethyl (2R)-3-(4-chloro-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 89 |  | Ethyl (2R)-3-(4-cyano-1H-imidazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 90 |  | Ethyl (2R)-3-(5-cyano-1H-imidazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 91 |  | Ethyl 2-({[2,6-dimethyl-4-(trifluoromethyl)phenyl]carbamoyl}oxy)-3-(1H-pyrazol-1-yl)propanoate |
| 92 |  | Ethyl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(4-methoxy-1H-pyrazol-1-yl)propanoate |
| 93 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate |
| 94 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrazin-2-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 95 |  | Ethyl (2R)-3-ethoxy-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 96 |  | Ethyl (2R)-3-(3-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 97 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-[4-(trifluoromethyl)-1H-pyrazol-1-yl]propanoate |
| 98 |  | (2R)-3-{4-[(dimethylamino)methyl]-1H-pyrazol-1-yl}-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoic acid hydrochloride |
| 99 |  | Ethyl 2-{[(2,4-dimethylthiophen-3-yl)carbamoyl]oxy}-3-(1H-pyrazol-1-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 100 |  | Ethyl 2-[({4,10-dioxatricyclo[7.3.0.0$^{3,7}$]dodeca-1,3(7),8-trien-2-yl}carbamoyl)oxy]-3-(1H-pyrazol-1-yl)propanoate |
| 101 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(2-methoxyethoxy)propanoate |
| 102 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(oxan-4-yloxy)propanoate |
| 103 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(5-methyl-1H-1,2,4-triazol-1-yl)propanoate |
| 104 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(propan-2-yloxy)propanoate |
| 105 |  | Ethyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(3-methyl-1H-1,2,4-triazol-1-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 106 |  | (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoic acid |
| 107 |  | Propan-2-yl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate |
| 108 |  | Cyclopentyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate |
| 109 |  | (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrazin-2-yl)propanoic acid |
| 110 |  | Propan-2-yl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrazin-2-yl)propanoate |
| 111 |  | Cyclopentyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyrazin-2-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 112 |  | Propan-2-yl (2R)-3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 113 |  | Cyclopentyl (2R)-3-(4-cyano-1H-pyrazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 114 |  | (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-1,2,4-triazol-1-yl)propanoic acid |
| 115 |  | Propan-2-yl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-1,2,4-triazol-1-yl)propanoate |
| 116 |  | Cyclopentyl (2R)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(1H-1,2,4-triazol-1-yl)propanoate |
| 117 |  | Propan-2-yl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(6-methylpyrazin-2-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 119 |  | Propan-2-yl 3-(5-cyanopyrazin-2-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 120 |  | Propan-2-yl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(2-methylpyrimidin-4-yl)propanoate |
| 121 |  | Propan-2-yl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(5-methylpyrazin-2-yl)propanoate |
| 123 |  | Propan-2-yl 2-{[(2-chloro-6-fluorophenyl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate |
| 124 |  | Propan-2-yl 2-{[(2,6-difluorophenyl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate |
| 125 |  | Propan-2-yl 2-{[(2,6-dichlorophenyl)carbamoyl]oxy}-3-(pyrimidin-2-yl)propanoate |

| Compound No. | Structure | Name |
|---|---|---|
| 126 |  | Propan-2-yl (2R)-3-(3-cyano-1H-1,2,4-triazol-1-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate |
| 127 |  | Propan-2-yl 2-[({bicyclo[2.2.2]octan-1-yl}carbamoyl)oxy]-3-(pyrimidin-2-yl)propanoate |
| 128 |  | Propan-2-yl 2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}-3-(pyridazin-4-yl)propanoate |
| 130 |  | Propan-2-yl 3-(5-cyanopyrimidin-2-yl)-2-{[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]oxy}propanoate. |

.

13. A pharmaceutical composition comprising the compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

14. Use of the compound of any one of claims 1-12, or a pharmaceutical salt thereof, or a pharmaceutical composition of claim 13, in the manufacture of a medicament for treating or preventing an autoinflammatory disorder, an autoimmune disorder, a neurodegenerative disease, or cancer.

15. The use of claim 14, wherein the disease or disorder is an autoinflammatory disorder or an autoimmune disorder;

optionally, the disease or disorder is selected from cryopyrin-associated autoinflammatory syndrome (CAPS; e.g., familial cold autoinflammatory syndrome (FCAS)), Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous and articular (CINCA) syndrome/ neonatal-onset multisystem inflammatory disease (NOMID), familial Mediterranean fever and nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), gout, rheumatoid arthritis, osteoarthritis, Crohn's disease, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), fibrosis, obesity, type 2 diabetes, multiple sclerosis and neuroinflammation occurring in protein misfolding diseases (e.g., Prion diseases).

16. The use of claim 14, wherein disease or disorder is a neurodegenerative disease;

optionally, the disease or disorder is Parkinson's disease or Alzheimer's disease.

17. The use of claim 14, wherein the disease or disorder is cancer;

optionally, the cancer is metastasising cancer, gastrointestinal cancer, skin cancer, non-small-cell lung carcinoma, or colorectal adenocarcinoma.